Protocol Ledger

NCT06942299 · Phase II · COMPLETED

A Study of AK0529 in Adults Patients Hospitalized With RSV Infection

Interventional Phase II clinical trial protocol NCT06942299 sponsored by Shanghai Ark Biopharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-20 Enrollment: 25 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06942299
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06942299
Protocol FieldVerified Registry Value
NCT IdentifierNCT06942299
Consolidated Lead SponsorShanghai Ark Biopharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment25 participants (ACTUAL)
Registered Start Date2023-07-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI